Recruiting

Rotarex System for Peripheral Artery Disease

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Rotarex(TM) Rotational Excisional Atherectomy System

Device
Who is being recruted

Arterial Occlusive Diseases+4

+ Arteriosclerosis

+ Cardiovascular Diseases

Over 22 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: September 2025
See protocol details

Summary

Principal SponsorC. R. Bard
Study ContactAdrija Sharma, PhDMore contacts
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: September 29, 2025

Actual date on which the first participant was enrolled.

This study is focused on evaluating a medical device called the Rotarex Rotational Excisional Atherectomy System for treating Peripheral Artery Disease (PAD). PAD is a condition where narrowed arteries reduce blood flow to the limbs, often causing pain and mobility issues. By assessing the real-world use of this device, the study aims to understand how well it helps patients with PAD and to gather more data on its effectiveness and safety. This research is crucial as it could lead to better treatment options for those affected by PAD, potentially improving their quality of life. Participants in this study will undergo treatment with the Rotarex device, which is designed to clear blocked arteries and restore blood flow. This is an interventional study, meaning it involves active treatment rather than just observation. The study plans to recruit around 600 subjects, who will be monitored to see how their condition improves after using the device. Although specific outcomes are not listed, the study will likely measure improvements in symptoms and any side effects or complications to evaluate the device's overall performance in real-world settings.

Official TitleA Prospective, Multicenter, Single Arm, Real-World Registry Assessing the Clinical Use of the Rotarex(TM) Rotational Excisional Atherectomy System (XTRACT Registry)
NCT07016698
Principal SponsorC. R. Bard
Study ContactAdrija Sharma, PhDMore contacts
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

600 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 22 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Arterial Occlusive DiseasesArteriosclerosisCardiovascular DiseasesVascular DiseasesPeripheral Vascular DiseasesAtherosclerosisPeripheral Arterial Disease

Criteria

Inclusion Criteria: 1. Subject or legally authorized representative provides written informed consent using an Informed Consent Form (ICF) that is reviewed and approved by the IRB for the site. 2. Subject is ≥22 years old at the time of signing the informed consent. 3. Subject must have a lesion(s) in their infra-inguinal peripheral arteries that can be treated with the RotarexTM Rotational Excisional Atherectomy System according to Instructions For Use (IFU). 4. Rutherford 2-5 for chronic limb ischemia and Rutherford I to IIb for acute limb ischemia. 5. Target lesion can be crossed intra-luminally by guidewire. 6. At least one patent native outflow artery to the foot, free from significant stenosis(≥50% stenosis as confirmed by angiography) (ChLI Cohort only, not applicable to ALI Cohort). Exclusion Criteria: 1. Subject is unable or unwilling to comply with follow-up procedures and visits. 2. Subject has a target lesion in a vessel with less than 3 mm in diameter. 3. Subject is participating in another device or drug clinical trial that interferes with this protocol and confounds results. 4. Treatment plan includes use of a thrombectomy and/or atherectomy device other than RotarexTM Rotational Excisional Atherectomy System. 5. Life expectancy is below 1 year. 6. Pregnant, planning to become pregnant during the course of the study or nursing a child.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Subjects treated with RotarexTM Rotational Excisional Atherectomy System

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 2 locations

Recruiting

Radiology and Imaging Specialists

Lakeland, United StatesOpen Radiology and Imaging Specialists in Google Maps
Recruiting

Vital Heart and Vein

Humble, United States
Recruiting
2 Study Centers